Rifapentine (BioDeep_00000006651)

 

Secondary id: BioDeep_00000275621

human metabolite blood metabolite Chemicals and Drugs Antibiotics


代谢物信息卡片


(7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,21Z)-26-[(1E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl]-2,15,17,23,27,29-hexahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6-oxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1(28),2,4,9,19,21,23,25(29),26-nonaen-13-yl acetate

化学式: C47H64N4O12 (876.4521)
中文名称: 利福喷丁
谱图信息: 最多检出来源 Homo sapiens(blood) 88.24%

分子结构信息

SMILES: CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C
InChI: InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1

描述信息

Rifapentine is only found in individuals that have used or taken this drug. It is an antibiotic drug used in the treatment of tuberculosis.Rifapentine has shown higher bacteriostatic and bactericidal activities especially against intracellular bacteria growing in human monocyte-derived macrophages. Rifapentine inhibits DNA-dependent RNA polymerase in susceptible strains of M. tuberculosis. Rifapentine acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death.
J - Antiinfectives for systemic use > J04 - Antimycobacterials > J04A - Drugs for treatment of tuberculosis > J04AB - Antibiotics
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007917 - Leprostatic Agents
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins
C254 - Anti-Infective Agent > C52588 - Antibacterial Agent > C280 - Antitubercular Agent

同义名列表

3 个代谢物同义名

(7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,21Z)-26-[(1E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl]-2,15,17,23,27,29-hexahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6-oxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1(28),2,4,9,19,21,23,25(29),26-nonaen-13-yl acetate; RIFAPENTINE; Rifapentine



数据库引用编号

17 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 9 ABCB1, ALB, BRAF, CDH2, CYP2B6, CYP3A4, MTOR, NAT2, PIK3CA
Peripheral membrane protein 3 CYP1B1, CYP2B6, MTOR
Endoplasmic reticulum membrane 6 AADAC, CD4, CYP1B1, CYP2B6, CYP3A4, MTOR
Nucleus 5 ALB, BRAF, MTOR, NAT2, NR1I2
cytosol 5 ALB, BRAF, MTOR, NAT2, PIK3CA
dendrite 1 MTOR
nuclear body 1 NR1I2
phagocytic vesicle 1 MTOR
centrosome 1 ALB
nucleoplasm 2 MTOR, NR1I2
Cell membrane 7 ABCB1, BRAF, CD4, CDH2, NAT2, SLCO1B1, SLCO1B3
Cytoplasmic side 1 MTOR
lamellipodium 2 CDH2, PIK3CA
Multi-pass membrane protein 4 ABCB1, NAT2, SLCO1B1, SLCO1B3
Golgi apparatus membrane 1 MTOR
cell junction 1 CDH2
cell surface 2 ABCB1, CDH2
glutamatergic synapse 1 BRAF
Golgi apparatus 1 ALB
Golgi membrane 1 MTOR
lysosomal membrane 1 MTOR
mitochondrial inner membrane 1 FECH
neuronal cell body 1 NAT2
postsynapse 1 BRAF
sarcolemma 1 CDH2
Lysosome 1 MTOR
Presynapse 1 BRAF
plasma membrane 9 ABCB1, BRAF, CD4, CDH2, IFNLR1, NAT2, PIK3CA, SLCO1B1, SLCO1B3
Membrane 10 AADAC, ABCB1, CDH2, CYP1B1, CYP3A4, IFNLR1, MTOR, NAT2, SLCO1B1, SLCO1B3
apical plasma membrane 2 ABCB1, CDH2
axon 1 NAT2
basolateral plasma membrane 4 CDH2, NAT2, SLCO1B1, SLCO1B3
extracellular exosome 4 ABCB1, ALB, BMP3, NAT2
Lysosome membrane 1 MTOR
endoplasmic reticulum 1 ALB
extracellular space 4 ALB, BMP3, CRP, IFNG
perinuclear region of cytoplasm 1 PIK3CA
adherens junction 1 CDH2
apicolateral plasma membrane 1 CDH2
intercalated disc 2 CDH2, PIK3CA
mitochondrion 3 BRAF, CYP1B1, FECH
protein-containing complex 1 ALB
intracellular membrane-bounded organelle 4 BRAF, CYP1B1, CYP2B6, CYP3A4
Microsome membrane 4 CYP1B1, CYP2B6, CYP3A4, MTOR
postsynaptic density 1 CDH2
TORC1 complex 1 MTOR
TORC2 complex 1 MTOR
Single-pass type I membrane protein 3 CD4, CDH2, IFNLR1
Secreted 4 ALB, BMP3, CRP, IFNG
extracellular region 4 ALB, BMP3, CRP, IFNG
Mitochondrion outer membrane 1 MTOR
mitochondrial outer membrane 1 MTOR
mitochondrial matrix 1 FECH
anchoring junction 1 ALB
transcription regulator complex 2 NAT2, NR1I2
external side of plasma membrane 1 CD4
Early endosome 1 CD4
apical part of cell 1 CDH2
cell-cell junction 1 CDH2
presynaptic active zone membrane 1 CDH2
Apical cell membrane 1 ABCB1
Cell membrane, sarcolemma 1 CDH2
Mitochondrion inner membrane 1 FECH
Membrane raft 1 CD4
focal adhesion 1 CDH2
Cell junction, adherens junction 1 CDH2
Nucleus, PML body 1 MTOR
PML body 1 MTOR
collagen-containing extracellular matrix 1 CDH2
fascia adherens 1 CDH2
neuron projection 2 BRAF, CDH2
ciliary basal body 1 ALB
chromatin 1 NR1I2
centriole 1 ALB
spindle pole 1 ALB
blood microparticle 1 ALB
Basolateral cell membrane 2 SLCO1B1, SLCO1B3
nuclear envelope 1 MTOR
Endomembrane system 1 MTOR
cell body 1 BRAF
intermediate filament cytoskeleton 1 NR1I2
basal plasma membrane 2 SLCO1B1, SLCO1B3
plasma membrane raft 1 CDH2
endoplasmic reticulum lumen 3 ALB, CD4, CDH2
platelet alpha granule lumen 1 ALB
phosphatidylinositol 3-kinase complex 1 PIK3CA
phosphatidylinositol 3-kinase complex, class IA 1 PIK3CA
clathrin-coated endocytic vesicle membrane 1 CD4
Basal cell membrane 2 SLCO1B1, SLCO1B3
external side of apical plasma membrane 2 ABCB1, NAT2
postsynaptic specialization membrane 1 CDH2
Cell junction, desmosome 1 CDH2
desmosome 1 CDH2
Cytoplasmic vesicle, phagosome 1 MTOR
catenin complex 1 CDH2
T cell receptor complex 1 CD4
NatA complex 1 NAT2
phosphatidylinositol 3-kinase complex, class IB 1 PIK3CA
ciliary transition fiber 1 ALB
interleukin-28 receptor complex 1 IFNLR1


文献列表

  • Bo-Huang Liou, Chih-Ning Cheng, Ya-Ting Lin, Yu-Jou Lin, Yu-Chung Chuang, Kuan-Yin Lin, Wen-Chun Liu, Shu-Wen Lin, Ching-Hua Kuo, Hsin-Yun Sun, Chien-Ching Hung. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. Journal of the International AIDS Society. 2021 11; 24(11):e25844. doi: 10.1002/jia2.25844. [PMID: 34822220]
  • Marc Weiner, Jon Gelfond, Teresa L Johnson-Pais, Melissa Engle, John L Johnson, William C Whitworth, Erin Bliven-Sizemore, Pheona Nsubuga, Susan E Dorman, Rada Savic. Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. The Journal of antimicrobial chemotherapy. 2021 02; 76(3):582-586. doi: 10.1093/jac/dkaa490. [PMID: 33374006]
  • J Surey, H R Stagg, T A Yates, M Lipman, P J White, A Charlett, L Muñoz, L Gosce, M X Rangaka, M Francis, V Hack, H Kunst, I Abubakar. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study. BMC infectious diseases. 2021 Jan; 21(1):90. doi: 10.1186/s12879-021-05766-9. [PMID: 33478428]
  • David W Haas, Anthony T Podany, Yajing Bao, Susan Swindells, Richard E Chaisson, Noluthando Mwelase, Khuanchai Supparatpinyo, Lerato Mohapi, Amita Gupta, Constance A Benson, Paxton Baker, Courtney V Fletcher. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenetics and genomics. 2021 01; 31(1):17-27. doi: 10.1097/fpc.0000000000000417. [PMID: 32815870]
  • Md Sorwer Alam Parvez, Md Adnan Karim, Mahmudul Hasan, Jomana Jaman, Ziaul Karim, Tohura Tahsin, Md Nazmul Hasan, Mohammad Jakir Hosen. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach. International journal of biological macromolecules. 2020 Nov; 163(?):1787-1797. doi: 10.1016/j.ijbiomac.2020.09.098. [PMID: 32950529]
  • Edwin Lam, Joseph Schaefer, Richard Zheng, Tingting Zhan, Walter K Kraft. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers. Clinical and translational science. 2020 11; 13(6):1244-1250. doi: 10.1111/cts.12810. [PMID: 32407548]
  • Jennifer E Hibma, Kendra K Radtke, Susan E Dorman, Amina Jindani, Kelly E Dooley, Marc Weiner, Helen M McIlleron, Radojka M Savic. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. American journal of respiratory and critical care medicine. 2020 09; 202(6):866-877. doi: 10.1164/rccm.201912-2489oc. [PMID: 32412342]
  • Jia-Yih Feng, Wei-Chang Huang, Shu-Min Lin, Tsai-Yu Wang, Susan Shin-Jung Lee, Chin-Chung Shu, Sheng-Wei Pan, Chung-Yu Chen, Chih-Bin Lin, Yu-Feng Wei, Chin-Lien Tung, Chiao-Ping Li, Wei-Juin Su. Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020 Jul; 96(?):550-557. doi: 10.1016/j.ijid.2020.05.009. [PMID: 32434083]
  • Jacques Simkins, Christian Donato-Santana, Michele Ileana Morris, Lilian Margarita Abbo, Jose Fernando Camargo, Shweta Anjan, Yoichiro Natori, Giselle Guerra. Treatment of latent tuberculosis infection with short-course regimens in potential living kidney donors. Transplant infectious disease : an official journal of the Transplantation Society. 2020 Apr; 22(2):e13244. doi: 10.1111/tid.13244. [PMID: 31923346]
  • Jose Francis, Simbarashe P Zvada, Paolo Denti, Mark Hatherill, Salome Charalambous, Stanley Mungofa, Rodney Dawson, Susan Dorman, Nikhil Gupte, Lubbe Wiesner, Amina Jindani, Thomas S Harrison, Adeniyi Olagunju, Deirdre Egan, Andrew Owen, Helen M McIlleron. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrobial agents and chemotherapy. 2019 04; 63(4):. doi: 10.1128/aac.01964-18. [PMID: 30670438]
  • Shang-Yi Lin, Yi-Wen Chiu, Po-Liang Lu, Shang-Jyh Hwang, Tun-Chieh Chen, Min-Han Hsieh, Yen-Hsu Chen. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2019 Feb; 52(1):158-162. doi: 10.1016/j.jmii.2018.05.003. [PMID: 29907535]
  • R K R Rajoli, A T Podany, D M Moss, S Swindells, C Flexner, A Owen, M Siccardi. Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2018 08; 22(8):937-944. doi: 10.5588/ijtld.17.0515. [PMID: 29991405]
  • Emílio V Lage, Joana Magalhães, Marina Pinheiro, Salette Reis. Effect of the alkyl group in the piperazine N-substitution on the therapeutic action of rifamycins: A drug-membrane interaction study. Chemico-biological interactions. 2018 Jun; 289(?):75-80. doi: 10.1016/j.cbi.2018.04.027. [PMID: 29709589]
  • Dalin Rifat, Brendan Prideaux, Radojka M Savic, Michael E Urbanowski, Teresa L Parsons, Brian Luna, Mark A Marzinke, Alvaro A Ordonez, Vincent P DeMarco, Sanjay K Jain, Veronique Dartois, William R Bishai, Kelly E Dooley. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Science translational medicine. 2018 04; 10(435):. doi: 10.1126/scitranslmed.aai7786. [PMID: 29618565]
  • Anushka Naidoo, Kogieleum Naidoo, Helen McIlleron, Sabiha Essack, Nesri Padayatchi. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis. Journal of clinical pharmacology. 2017 Nov; 57(11):1369-1386. doi: 10.1002/jcph.968. [PMID: 28741299]
  • Yuwu Liu, Jiming Zhu, Dianming Jiang. Release characteristics of bone‑like hydroxyapatite/poly amino acid loaded with rifapentine microspheres in vivo. Molecular medicine reports. 2017 Aug; 16(2):1425-1430. doi: 10.3892/mmr.2017.6747. [PMID: 28627673]
  • Jacques Simkins, Lilian Margarita Abbo, Jose Fernando Camargo, Rossana Rosa, Michele Ileana Morris. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates. Transplantation. 2017 06; 101(6):1468-1472. doi: 10.1097/tp.0000000000001329. [PMID: 27548035]
  • B M Knoll, R Nog, Y Wu, A Dhand. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates. Infection. 2017 Jun; 45(3):335-339. doi: 10.1007/s15010-017-1004-5. [PMID: 28276008]
  • Thaigarajan Parumasivam, Anneliese S Ashhurst, Gayathri Nagalingam, Warwick J Britton, Hak-Kim Chan. Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation. Molecular pharmaceutics. 2017 01; 14(1):328-335. doi: 10.1021/acs.molpharmaceut.6b00905. [PMID: 27977216]
  • Chunlan Zheng, Xiufen Hu, Li Zhao, Minhui Hu, Feng Gao. Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?. Drug design, development and therapy. 2017; 11(?):2957-2968. doi: 10.2147/dddt.s146506. [PMID: 29066867]
  • Jieyun Huang, Zhi Chen, Ying Li, Li Li, Guangyu Zhang. Rifapentine-linezolid-loaded PLGA microspheres for interventional therapy of cavitary pulmonary tuberculosis: preparation and in vitro characterization. Drug design, development and therapy. 2017; 11(?):585-592. doi: 10.2147/dddt.s127897. [PMID: 28424536]
  • Jacques Simkins, Michele I Morris, Lilian M Abbo, Jose F Camargo. Severe hypertension after initiation of rifapentine/isoniazid for latent tuberculosis in renal transplant candidates. Transplant international : official journal of the European Society for Organ Transplantation. 2017 Jan; 30(1):108-109. doi: 10.1111/tri.12881. [PMID: 28032405]
  • Nuggehally R Srinivas. Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion. Xenobiotica; the fate of foreign compounds in biological systems. 2016 Sep; 46(9):784-92. doi: 10.3109/00498254.2015.1121554. [PMID: 26711252]
  • Todd J Zurlinden, Garrett J Eppers, Brad Reisfeld. Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans. Antimicrobial agents and chemotherapy. 2016 08; 60(8):4860-8. doi: 10.1128/aac.00031-16. [PMID: 27270284]
  • Sébastien Goutal, Sylvain Auvity, Tiphaine Legrand, Fanny Hauquier, Salvatore Cisternino, Hélène Chapy, Wadad Saba, Nicolas Tournier. Validation of a simple HPLC-UV method for rifampicin determination in plasma: Application to the study of rifampicin arteriovenous concentration gradient. Journal of pharmaceutical and biomedical analysis. 2016 May; 123(?):173-8. doi: 10.1016/j.jpba.2016.02.013. [PMID: 26907700]
  • K P Ostrovskiy, E R Pereverzeva, I D Treshchalin, N S Osipova, M I Treshchalin, E V Voznyakovskaya, V Yu Balabanyan, O O Maksimenko, S E Gelperina. [Toxicological Evaluation of Intravenous Formulation of Rifapentine.]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]. 2016 ; 61(7-8):15-21. doi: NULL. [PMID: 29533556]
  • Haileyesus Getahun, Alberto Matteelli, Ibrahim Abubakar, Mohamed Abdel Aziz, Annabel Baddeley, Draurio Barreira, Saskia Den Boon, Susana Marta Borroto Gutierrez, Judith Bruchfeld, Erlina Burhan, Solange Cavalcante, Rolando Cedillos, Richard Chaisson, Cynthia Bin-Eng Chee, Lucy Chesire, Elizabeth Corbett, Masoud Dara, Justin Denholm, Gerard de Vries, Dennis Falzon, Nathan Ford, Margaret Gale-Rowe, Chris Gilpin, Enrico Girardi, Un-Yeong Go, Darshini Govindasamy, Alison D Grant, Malgorzata Grzemska, Ross Harris, C Robert Horsburgh, Asker Ismayilov, Ernesto Jaramillo, Sandra Kik, Katharina Kranzer, Christian Lienhardt, Philip LoBue, Knut Lönnroth, Guy Marks, Dick Menzies, Giovanni Battista Migliori, Davide Mosca, Ya Diul Mukadi, Alwyn Mwinga, Lisa Nelson, Nobuyuki Nishikiori, Anouk Oordt-Speets, Molebogeng Xheedha Rangaka, Andreas Reis, Lisa Rotz, Andreas Sandgren, Monica Sañé Schepisi, Holger J Schünemann, Surender Kumar Sharma, Giovanni Sotgiu, Helen R Stagg, Timothy R Sterling, Tamara Tayeb, Mukund Uplekar, Marieke J van der Werf, Wim Vandevelde, Femke van Kessel, Anna van't Hoog, Jay K Varma, Natalia Vezhnina, Constantia Voniatis, Marije Vonk Noordegraaf-Schouten, Diana Weil, Karin Weyer, Robert John Wilkinson, Takashi Yoshiyama, Jean Pierre Zellweger, Mario Raviglione. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. The European respiratory journal. 2015 Dec; 46(6):1563-76. doi: 10.1183/13993003.01245-2015. [PMID: 26405286]
  • John G Y Chan, Anneliese S Tyne, Angel Pang, Andrew J McLachlan, Vidya Perera, Joseph C Y Chan, Warwick J Britton, Hak Kim Chan, Colin C Duke, Paul M Young, Daniela Traini. Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. International journal of antimicrobial agents. 2015 Mar; 45(3):319-23. doi: 10.1016/j.ijantimicag.2014.11.009. [PMID: 25554469]
  • Lee C Winchester, Anthony T Podany, Joshua S Baldwin, Brian L Robbins, Courtney V Fletcher. Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS. Journal of pharmaceutical and biomedical analysis. 2015 Feb; 104(?):55-61. doi: 10.1016/j.jpba.2014.11.011. [PMID: 25481085]
  • Teresa L Parsons, Mark A Marzinke, Thuy Hoang, Erin Bliven-Sizemore, Marc Weiner, William R Mac Kenzie, Susan E Dorman, Kelly E Dooley. Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis. Antimicrobial agents and chemotherapy. 2014 Nov; 58(11):6747-57. doi: 10.1128/aac.03607-14. [PMID: 25182637]
  • Eric F Egelund, Marc Weiner, Rajendra P Singh, Thomas J Prihoda, Jonathon A L Gelfond, Hartmut Derendorf, William R Mac Kenzie, Charles A Peloquin. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrobial agents and chemotherapy. 2014 Aug; 58(8):4904-10. doi: 10.1128/aac.01730-13. [PMID: 24841270]
  • John Gar Yan Chan, Anneliese S Tyne, Angel Pang, Hak-Kim Chan, Paul M Young, Warwick J Britton, Colin C Duke, Daniela Traini. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. Pharmaceutical research. 2014 May; 31(5):1239-53. doi: 10.1007/s11095-013-1245-7. [PMID: 24242939]
  • Arpana Patil-Gadhe, Varsha Pokharkar. Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach. Pulmonary pharmacology & therapeutics. 2014 Apr; 27(2):197-207. doi: 10.1016/j.pupt.2013.07.006. [PMID: 23916767]
  • Marc Weiner, Eric F Egelund, Melissa Engle, Melissa Kiser, Thomas J Prihoda, Jonathan A L Gelfond, William Mac Kenzie, Charles A Peloquin. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. The Journal of antimicrobial chemotherapy. 2014 Apr; 69(4):1079-85. doi: 10.1093/jac/dkt483. [PMID: 24343893]
  • Diego López de Castilla, Robert M Rakita, Christopher E Spitters, Masahiro Narita, Rupali Jain, Ajit P Limaye. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates. Transplantation. 2014 Jan; 97(2):206-11. doi: 10.1097/tp.0b013e3182a94a2f. [PMID: 24142036]
  • Noton K Dutta, Abdullah Alsultan, Charles A Peloquin, Petros C Karakousis. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. Antimicrobial agents and chemotherapy. 2013 Mar; 57(3):1535-7. doi: 10.1128/aac.01933-12. [PMID: 23295923]
  • Anne M Baciewicz, Cary R Chrisman, Christopher K Finch, Timothy H Self. Update on rifampin, rifabutin, and rifapentine drug interactions. Current medical research and opinion. 2013 Jan; 29(1):1-12. doi: 10.1185/03007995.2012.747952. [PMID: 23136913]
  • K E Dooley, E E Bliven-Sizemore, M Weiner, Y Lu, E L Nuermberger, W C Hubbard, E J Fuchs, M T Melia, W J Burman, S E Dorman. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clinical pharmacology and therapeutics. 2012 May; 91(5):881-8. doi: 10.1038/clpt.2011.323. [PMID: 22472995]
  • Deepak Almeida, Paul J Converse, Zahoor Ahmad, Kelly E Dooley, Eric L Nuermberger, Jacques H Grosset. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. PLoS neglected tropical diseases. 2011 Jan; 5(1):e933. doi: 10.1371/journal.pntd.0000933. [PMID: 21245920]
  • Simbarashe P Zvada, Jan-Stefan Van Der Walt, Peter J Smith, P Bernard Fourie, Giorgio Roscigno, Denis Mitchison, Ulrika S H Simonsson, Helen M McIlleron. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrobial agents and chemotherapy. 2010 Aug; 54(8):3390-4. doi: 10.1128/aac.00345-10. [PMID: 20516273]
  • Kelly Dooley, Charles Flexner, Judith Hackman, Charles A Peloquin, Eric Nuermberger, Richard E Chaisson, Susan E Dorman. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrobial agents and chemotherapy. 2008 Nov; 52(11):4037-42. doi: 10.1128/aac.00554-08. [PMID: 18765687]
  • Xing-Cong Li, Melissa R Jacob, Shabana I Khan, M Khalid Ashfaq, K Suresh Babu, Ameeta K Agarwal, Hala N Elsohly, Susan P Manly, Alice M Clark. Potent in vitro antifungal activities of naturally occurring acetylenic acids. Antimicrobial agents and chemotherapy. 2008 Jul; 52(7):2442-8. doi: 10.1128/aac.01297-07. [PMID: 18458131]
  • Sharon L Ripp, Jessica B Mills, Odette A Fahmi, Kristen A Trevena, Jennifer L Liras, Tristan S Maurer, Sonia M de Morais. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug metabolism and disposition: the biological fate of chemicals. 2006 Oct; 34(10):1742-8. doi: 10.1124/dmd.106.010132. [PMID: 16837568]
  • F A Sirgel, J S Maritz, A Venter, G Langdon, P J Smith, P R Donald. Monitoring the ingestion of anti-tuberculosis drugs by simple non-invasive methods. International journal of pharmaceutics. 2006 Jan; 307(2):182-7. doi: 10.1016/j.ijpharm.2005.09.033. [PMID: 16303269]
  • Frik A Sirgel, P Bernard Fourie, Peter R Donald, Nesri Padayatchi, Roxana Rustomjee, Jonathan Levin, Giorgio Roscigno, Jennifer Norman, Helen McIlleron, Denis A Mitchison. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. American journal of respiratory and critical care medicine. 2005 Jul; 172(1):128-35. doi: 10.1164/rccm.200411-1557oc. [PMID: 15805182]
  • G Langdon, J J Wilkins, P J Smith, H McIlleron. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2004 Jul; 8(7):862-7. doi: NULL. [PMID: 15260278]
  • Marc Weiner, Naomi Bock, Charles A Peloquin, William J Burman, Awal Khan, Andrew Vernon, Zhen Zhao, Stephen Weis, Timothy R Sterling, Katherine Hayden, Stefan Goldberg. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. American journal of respiratory and critical care medicine. 2004 Jun; 169(11):1191-7. doi: 10.1164/rccm.200311-1612oc. [PMID: 14962821]
  • Debra Benator, Mondira Bhattacharya, Lorna Bozeman, William Burman, Antonino Cantazaro, Richard Chaisson, Fred Gordin, C Robert Horsburgh, James Horton, Awal Khan, Christopher Lahart, Beverly Metchock, Constance Pachucki, Llewellyn Stanton, Andrew Vernon, M Elsa Villarino, Yong Chen Wang, Marc Weiner, Stephen Weis. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet (London, England). 2002 Aug; 360(9332):528-34. doi: 10.1016/s0140-6736(02)09742-8. [PMID: 12241657]
  • J E Conte, J A Golden, M McQuitty, J Kipps, E T Lin, E Zurlinden. Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. Antimicrobial agents and chemotherapy. 2000 Apr; 44(4):985-90. doi: 10.1128/aac.44.4.985-990.2000. [PMID: 10722501]
  • J D Marshall, S Abdel-Rahman, K Johnson, R E Kauffman, G L Kearns. Rifapentine pharmacokinetics in adolescents. The Pediatric infectious disease journal. 1999 Oct; 18(10):882-8. doi: 10.1097/00006454-199910000-00009. [PMID: 10530584]
  • A Vernon, W Burman, D Benator, A Khan, L Bozeman. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet (London, England). 1999 May; 353(9167):1843-7. doi: 10.1016/s0140-6736(98)11467-8. [PMID: 10359410]
  • A C Keung, R C Owens, M G Eller, S J Weir, D P Nicolau, C H Nightingale. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. Antimicrobial agents and chemotherapy. 1999 May; 43(5):1230-3. doi: 10.1128/aac.43.5.1230. [PMID: 10223941]
  • A Keung, M G Eller, K A McKenzie, S J Weir. Single and multiple dose pharmacokinetics of rifapentine in man: part II. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 1999 May; 3(5):437-44. doi: . [PMID: 10331734]
  • A Keung, K Reith, M G Eller, K A McKenzie, L Cheng, S J Weir. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 1999 May; 3(5):426-36. doi: . [PMID: 10331733]
  • A C Keung, M G Eller, S J Weir. Single-dose pharmacokinetics of rifapentine in elderly men. Pharmaceutical research. 1998 Aug; 15(8):1286-91. doi: 10.1023/a:1011960428896. [PMID: 9706063]
  • K Reith, A Keung, P C Toren, L Cheng, M G Eller, S J Weir. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug metabolism and disposition: the biological fate of chemicals. 1998 Aug; 26(8):732-8. doi: NULL. [PMID: 9698286]
  • W B Emary, P C Toren, B Mathews, K Huh. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys. Drug metabolism and disposition: the biological fate of chemicals. 1998 Aug; 26(8):725-31. doi: . [PMID: 9698285]
  • A C Keung, M G Eller, S J Weir. Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction. Journal of clinical pharmacology. 1998 Jun; 38(6):517-24. doi: 10.1002/j.1552-4604.1998.tb05789.x. [PMID: 9650541]
  • C M Tam, S L Chan, C W Lam, C C Leung, K M Kam, J S Morris, D A Mitchison. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. American journal of respiratory and critical care medicine. 1998 Jun; 157(6 Pt 1):1726-33. doi: 10.1164/ajrccm.157.6.9707037. [PMID: 9620898]
  • A C Keung, M G Eller, S J Weir. Single-dose pharmacokinetics of rifapentine in women. Journal of pharmacokinetics and biopharmaceutics. 1998 Feb; 26(1):75-85. doi: 10.1023/a:1023276808298. [PMID: 9773393]
  • C M Tam, S L Chan, C W Lam, J M Dickinson, D A Mitchison. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 1997 Oct; 1(5):411-6. doi: NULL. [PMID: 9441094]
  • M T Kenny, D L Reynolds, M A Brackman, J K Dulworth. Comparison of biological and chemical assays for the quantitation of rifapentine in human plasma. Diagnostic microbiology and infectious disease. 1997 Apr; 27(4):107-11. doi: 10.1016/s0732-8893(97)00027-8. [PMID: 9154405]
  • X He, J Wang, X Liu, X Chen. High-performance liquid chromatography assay of rifapentine in human serum. Journal of chromatography. B, Biomedical applications. 1996 Jun; 681(2):412-5. doi: 10.1016/0378-4347(96)00021-7. [PMID: 8811456]
  • B Ji, C Truffot-Pernot, C Lacroix, M C Raviglione, R J O'Brien, P Olliaro, G Roscigno, J Grosset. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. The American review of respiratory disease. 1993 Dec; 148(6 Pt 1):1541-6. doi: 10.1164/ajrccm/148.6_pt_1.1541. [PMID: 8256897]
  • L E Bermudez, M Wu, L S Young, C B Inderlied. Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex. The Journal of infectious diseases. 1992 Oct; 166(4):923-6. doi: 10.1093/infdis/166.4.923. [PMID: 1445599]
  • J Dhillon, J M Dickinson, J A Guy, T K Ng, D A Mitchison. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 1992 Apr; 73(2):116-23. doi: 10.1016/0962-8479(92)90066-s. [PMID: 1643297]
  • H S Lee, H C Shin, S S Han, J K Roh. High-performance liquid chromatographic determination of rifapentine in serum using column switching. Journal of chromatography. 1992 Feb; 574(1):175-8. doi: 10.1016/0378-4347(92)80116-8. [PMID: 1629284]
  • E Riva, R Merati, L Cavenaghi. High-performance liquid chromatographic determination of rifapentine and its metabolite in human plasma by direct injection into a shielded hydrophobic phase column. Journal of chromatography. 1991 Aug; 553(1-2):35-40. doi: 10.1016/s0021-9673(01)88469-7. [PMID: 1787163]
  • C Perronne, A Gikas, C Truffot-Pernot, J Grosset, J L Vilde, J J Pocidalo. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrobial agents and chemotherapy. 1991 Jul; 35(7):1356-9. doi: 10.1128/aac.35.7.1356. [PMID: 1656860]
  • L B Heifets, P J Lindholm-Levy, M A Flory. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. The American review of respiratory disease. 1990 Mar; 141(3):626-30. doi: 10.1164/ajrccm/141.3.626. [PMID: 2155555]
  • B Y Yan. [Absorption and elimination of cyclopentyl-rifamycin in man]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases. 1987 Oct; 10(5):267-8, 307. doi: NULL. [PMID: 3450413]
  • A Assandri, B Ratti, T Cristina. Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. The Journal of antibiotics. 1984 Sep; 37(9):1066-75. doi: 10.7164/antibiotics.37.1066. [PMID: 6501103]
  • P Iversen, O S Nielsen, K M Jensen, P O Madsen. Comparison of concentrations of rifampin and a new rifamycin derivative, DL 473, in canine bone. Antimicrobial agents and chemotherapy. 1983 Feb; 23(2):338-40. doi: 10.1128/aac.23.2.338. [PMID: 6838192]
  • B Ratti, A Toselli, R Rosina Parenti. Method for determination of DL 473-IT and its metabolite L 14583 in plasma of humans, monkeys and rats. Il Farmaco; edizione pratica. 1981 Jul; 36(7):319-28. doi: NULL. [PMID: 6791958]